Premium
P4‐018: IMPAIRED CHRONIC PAIN‐LIKE BEHAVIOUR AND DISRUPTION OF OPIOIDERGIC SYSTEM IN TASTPM MODEL OF ALZHEIMER'S DISEASE
Author(s) -
Aman Yahyah,
Pitcher Thomas,
Ballard Clive,
Malcangio Marzia
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.06.2420
Subject(s) - opioidergic , medicine , allodynia , chronic pain , nociception , osteoarthritis , morphine , (+) naloxone , opioid , anesthesia , analgesic , endocrinology , hyperalgesia , physical therapy , pathology , receptor , alternative medicine
Background:There are currently more than 40million peopleworldwide with Alzheimer’s disease number which is expected to increase to more than 80 million by 2050. Developing effective therapies is an increasingly urgent priority. The current study involves a careful review of the NIH.GOV clinical trial registry to assess the pipeline of ongoing trials evaluating novel therapies as well as safe and effective symptomatic therapies to treat associated neuropsychiatric symptoms and more effective pain treatment. Methods:All active clinical trials from the international NIH database (clinicaltrials.gov) were examined to make a full assessment of the number of compounds currently being pulled through the clinical trial pipeline. Selection criteria was applied to exclude natural products and cholinesterase inhibitor studies ensuring no duplicates of compounds through extension studies. Results:The analysis showed that there are currently more than 40 fold more active clinical trials for cancer than for Alzheimer’s disease. Through application of the selection criteria the analysis identified only 20 drugs/ small molecules and 9 biologics in phase 2 or phase 3 clinical trials with (23 in phase 2, 4 in phase 2/3 and 7 in phase 3, 5 amyloid immunotherapy treatments, 5 other amyloid treatment approaches, 4 treatments targeting tau, 3 neurotransmitter based therapies, 3 re1⁄4positioned agents with multiple targets, 1 regenerative treatment, 1 treatment targeting inflammation and 7 treatments with a range of miscellaneous targets). Conclusions:The pipeline of effective treatments and therapies for Alzheimer’s disease is critically low despite the increasingly urgent and unmet need for further treatments and therapies. Disappointingly, the pipeline has not improved since 2102. There is a need for new approaches to smart clinical trial design to substantially increase the number of compounds in phase 2 trials and enable more efficient and more costeffective pull through of evolving treatments.